

ASX Announcement

Recce Awarded AusIndustry Advanced Overseas (R&D) Finding for up to A\$85m for Synthetic Anti-Infective Development Program

Sydney Australia, 16 December 2025: Recce Pharmaceuticals Limited (**ASX:RCE**, **FSE:R9Q**), (**Recce** or **the Company**) a leading developer of a New Class of Synthetic Anti-Infectives, is pleased to announce it has received an Advanced Overseas Finding for up to **A\$85 million** for Synthetic Antibiotic Research & Development (R&D) applicable expenditure by Department of Industry, Science and Resources.



Australian Government
Department of Industry,
Science and Resources

Research and Development Tax Incentive

R&D Tax Incentive: Advance and Overseas Finding Assessment Report

Case Details

Company Name	RECCE PHARMACEUTICALS LTD
ABN	73124849065
Project Title	Development and testing of a new synthetic antibiotic against superbugs
Project Value	\$84,921,710.00
Finding Type	Finding for Overseas R&D Activities (s28A & s28C of the IR&D Act)
Income years of application for finding	2024-2025 2025-2026 2026-2027

The Advanced Overseas Finding provides confirmation that Recce's R&D activities undertaken outside Australia are eligible and qualify for the 43.5% R&D Tax Incentive, extending the rebate beyond domestic activities for a three-year period. This finding does not constitute a grant, or an upfront payment of the amount awarded.

The Australian Government extends the R&D cash rebate to the Company capturing its local and overseas R&D activities, for a period of three years. This Finding covers Recce's domestic and overseas activities, including its Phase 3 Diabetic Foot Infection (DFI) clinical trial in Indonesia and further overseas R&D programs conducted throughout the Company's infectious disease portfolio.



ASX: RCE, **FSE:** R9Q

Head Office: Level 15, 1 Farrer Place, Governor Macquarie Tower, SYDNEY NSW 2000 **T** +61 (2) 9000 1907

R&D Centre - Perth: Suite 10, 3 Brodie Hall Drive, Technology Park, BENTLEY WA 6102 **T** +61 (8) 9362 9860

Washington Office: 1717 Pennsylvania Avenue NW, Suite 1025, WASHINGTON DC 20006 USA

Recce Pharmaceuticals' CEO, James Graham said "This represents one of the largest Advance and Overseas Findings in Australian history, confirming eligibility for up to A\$85 million in R&D expenditure under the Australian Government's R&D Tax Incentive. This binding decision supports our global anti-infective programs - extending the 43.5% rebate not only locally, but to activities conducted around the world. This is highlighted by key late-stage clinical programs, including patient dosing in our Phase III clinical trial for DFI. We thank the Australian Government for recognising the importance of our work in efforts to make antibiotic resistance history."

This announcement has been approved for release by Recce Pharmaceuticals Board.

Media and Investor Relations

Chief Executive Officer

James Graham
Recce Pharmaceuticals Ltd
james.graham@recce.com.au

Australia

Andrew Geddes
Seed Media
andrew@seedmedia.com.au

USA & Europe

Guillaume van Renterghem
LifeSci Advisors
gvanrenterghem@lifesciadvisors.com

About Recce Pharmaceuticals Ltd

Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q) is developing a New Class of Synthetic Anti-Infectives designed to address the urgent global health problems of antibiotic-resistant superbugs.

Recce's anti-infective pipeline includes three patented, broad-spectrum, synthetic polymer anti-infectives: RECCE® 327 (R327) as an intravenous and topical therapy that is being developed for the treatment of serious and potentially life-threatening infections due to Gram-positive and Gram-negative bacteria, including their superbug forms; RECCE® 435 (R435) as an orally administered therapy for bacterial infections; and RECCE® 529 (R529) for viral infections. Through their multi-layered mechanisms of action, Recce's anti-infectives have the potential to overcome the processes utilised by bacteria and viruses to overcome resistance – a current challenge facing existing antibiotics.

The World Health Organization (WHO) added R327, R435, and R529 to its list of antibacterial products in clinical development for priority pathogens, recognising Recce's efforts to combat antimicrobial resistance. The FDA granted R327 Qualified Infectious Disease Product designation under the Generating Antibiotic Initiatives Now (GAIN) Act, providing Fast Track Designation and 10 years of market exclusivity post approval. R327 is also included on The Pew Charitable Trusts' Global New Antibiotics in Development Pipeline as the sole synthetic polymer and sepsis drug candidate in development.

Recce wholly owns its automated manufacturing, supporting current clinical trials. Recce's anti-infective pipeline aims to address synergistic, unmet medical needs by leveraging its unique technologies.

Media and Investor Relations

Chief Executive Officer

James Graham
Recce Pharmaceuticals Ltd
james.graham@recce.com.au

Australia

Andrew Geddes
Seed Media
andrew@seedmedia.com.au

USA & Europe

Guillaume van Renterghem
LifeSci Advisors
gvanrenterghem@lifesciadvisors.com